{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:21:14Z","timestamp":1786947674386,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106728","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:58:11Z","timestamp":1757170691000},"page":"106728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Disease modifying therapy after autologous haematopoietic stem cell transplantation in multiple sclerosis patients: 10-years follow-up data from Lithuania"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2111-363X","authenticated-orcid":false,"given":"Nata\u0161a","family":"Giedraitien\u0117","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintaras","family":"Kaubrys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Kizlaitien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdas","family":"Pe\u010deli\u016bnas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u016brat\u0117","family":"Dementavi\u010dien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrius","family":"\u017du\u010denka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laimonas","family":"Gri\u0161kevi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2025.106728_bib0029","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/jnnp-2013-307207","article-title":"Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience","volume":"85","author":"Burman","year":"2014","journal-title":"J. Neurol Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106728_bib0014","doi-asserted-by":"crossref","unstructured":"Burt R.K., Balabanov R., Han X., Sharrack B., Morgan A., Quigley K., et al. JAMA. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. 2015 Jan 20;313(3):275\u201384.","DOI":"10.1001\/jama.2014.17986"},{"issue":"2","key":"10.1016\/j.msard.2025.106728_bib0008","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.msard.2025.106728_bib0002","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00415-021-10820-2","article-title":"Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis","volume":"269","author":"Burt","year":"2022","journal-title":"J. Neurol"},{"issue":"7","key":"10.1016\/j.msard.2025.106728_bib0019","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10072-017-2933-6","article-title":"Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis","volume":"38","author":"Casanova","year":"2017","journal-title":"Neurol. Sci"},{"key":"10.1016\/j.msard.2025.106728_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.813957","article-title":"Immune reconstitution following autologous hematopoietic stem cell transplantation for multiple sclerosis: a review on behalf of the EBMT Autoimmune Diseases Working Party","volume":"12","author":"Cencioni","year":"2022","journal-title":"Front. Immunol"},{"issue":"5","key":"10.1016\/j.msard.2025.106728_bib0017","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2019.02.014","article-title":"Autologous hematopoietic cell Transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation","volume":"25","author":"Cohen","year":"2019","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.msard.2025.106728_bib0024","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10072-016-2564-3","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience","volume":"37","author":"Curr\u00f2","year":"2016","journal-title":"Neurol. Sci"},{"issue":"1","key":"10.1016\/j.msard.2025.106728_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78160-1","article-title":"Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis","volume":"10","author":"Giedraitiene","year":"2020","journal-title":"Sci. Rep"},{"issue":"4","key":"10.1016\/j.msard.2025.106728_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2025.106728_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/B978-0-323-90242-7.00019-5","article-title":"Ongoing randomized clinical trials on HSCT in multiple sclerosis","volume":"202","author":"Inglese","year":"2024","journal-title":"Handb Clin. Neurol"},{"issue":"7","key":"10.1016\/j.msard.2025.106728_bib0009","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis","volume":"80","author":"Kalincik","year":"2023","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.msard.2025.106728_bib0030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/13524585241231665","article-title":"Autologous hematopoietic stem cell transplantation for multiple sclerosis: long-term follow-up data from Norway","volume":"30","author":"Kvistad","year":"2024","journal-title":"Mult. Scler"},{"issue":"10","key":"10.1016\/j.msard.2025.106728_bib0007","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106728_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103861","article-title":"Disease modifying therapy management of multiple sclerosis after stem cell therapies: a retrospective case series","volume":"63","author":"Manzano","year":"2022","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2025.106728_bib0006","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fimmu.2018.00410","article-title":"Regenerating immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant","volume":"9","author":"Massey","year":"2018","journal-title":"Front. Immunol"},{"issue":"2","key":"10.1016\/j.msard.2025.106728_bib0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"National Medical Advisory Committee of the National Multiple Sclerosis Society. Autologous hematopoietic stem cell transplant in Multiple Sclerosis: recommendations of the National Multiple Sclerosis Society","volume":"78","author":"Miller","year":"2021","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.msard.2025.106728_bib0004","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol"},{"issue":"4","key":"10.1016\/j.msard.2025.106728_bib0023","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.msard.2025.106728_bib0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat. Rev. Neurol"},{"issue":"9","key":"10.1016\/j.msard.2025.106728_bib0028","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","article-title":"High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS","volume":"88","author":"Nash","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106728_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62726-4","article-title":"Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Nawar","year":"2024","journal-title":"Sci. Rep"},{"issue":"4","key":"10.1016\/j.msard.2025.106728_bib0026","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/jcm11040942","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis patients: monocentric case series and systematic review of the literature","volume":"11","author":"Patti","year":"2022","journal-title":"J. Clin. Med"},{"issue":"1","key":"10.1016\/j.msard.2025.106728_bib0012","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ncl.2023.06.002","article-title":"Autologous hematopoietic stem cell transplantation to treat multiple sclerosis","volume":"42","author":"Ross","year":"2024","journal-title":"Neurol. Clin"},{"issue":"2","key":"10.1016\/j.msard.2025.106728_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow. Transplant"},{"issue":"2","key":"10.1016\/j.msard.2025.106728_bib0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jnnp-2023-331864","article-title":"Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study","volume":"95","author":"Silfverberg","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiat"},{"issue":"2","key":"10.1016\/j.msard.2025.106728_bib0027","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1352458516645670","article-title":"NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs","volume":"23","author":"Sormani","year":"2017","journal-title":"Mult. Scler"},{"issue":"7","key":"10.1016\/j.msard.2025.106728_bib0013","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41409-021-01276-z","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a global approval and availability review","volume":"56","author":"Stathopoulos","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.msard.2025.106728_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.msard.2025.106728_bib0001","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1007\/s00415-022-11063-5","article-title":"The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis","volume":"269","author":"Willison","year":"2022","journal-title":"J. Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:16:15Z","timestamp":1774998975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"alternative-id":["S2211034825004705"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106728","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease modifying therapy after autologous haematopoietic stem cell transplantation in multiple sclerosis patients: 10-years follow-up data from Lithuania","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106728"}}